These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22611212)

  • 1. Pharmaceutical evaluation of compounded trilostane products.
    Cook AK; Nieuwoudt CD; Longhofer SL
    J Am Anim Hosp Assoc; 2012; 48(4):228-33. PubMed ID: 22611212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of commercially manufactured and compounded protamine zinc insulin.
    Scott-Moncrieff JC; Moore GE; Coe J; Lynn RC; Gwin W; Petzold R
    J Am Vet Med Assoc; 2012 Mar; 240(5):600-5. PubMed ID: 22332631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of compounded trilostane suspension in cod liver oil.
    Crosby J; Brown S
    Vet J; 2017 Oct; 228():15-17. PubMed ID: 29153102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy and precision of compounded ciclosporin capsules and solution.
    Umstead ME; Boothe DM; Cruz-Espindola C; Macdonald JM; Kennis R; Angarano D
    Vet Dermatol; 2012 Oct; 23(5):431-e82. PubMed ID: 22970897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of compounded trilostane packets for dogs with naturally occurring hyperadrenocorticism.
    Nam S; Kim TW; Song KH; Feldman EC; Seo KW
    J Vet Intern Med; 2021 Jul; 35(4):1729-1732. PubMed ID: 34114230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality assessment of fluconazole capsules and oral suspensions compounded by pharmacies located in the United States.
    Laporte CM; Cruz-Espindola C; Thungrat K; Schick AE; Lewis TP; Boothe DM
    Am J Vet Res; 2017 Apr; 78(4):421-432. PubMed ID: 28346002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of testosterone concentrations in compounded testosterone products.
    Grober ED; Garbens A; Božović A; Kulasingam V; Fanipour M; Diamandis EP
    J Sex Med; 2015 Jun; 12(6):1381-8. PubMed ID: 25963000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
    Vaughan MA; Feldman EC; Hoar BR; Nelson RW
    J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
    Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
    Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the quality of simvastatin capsules from compounding pharmacies.
    Markman BE; Rosa PC; Koschtschak MR
    Rev Saude Publica; 2010 Dec; 44(6):1055-62. PubMed ID: 21107503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
    Feldman EC
    J Am Vet Med Assoc; 2011 Jun; 238(11):1441-51. PubMed ID: 21627507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro studies on the release of morphine sulfate from compounded slow-release morphine-sulfate capsules.
    Webster KD; Al-Achi A; Greenwood R
    Int J Pharm Compd; 1999; 3(5):409-11. PubMed ID: 23985766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of compounded hydrocortisone capsules used in the treatment of children.
    Neumann U; Burau D; Spielmann S; Whitaker MJ; Ross RJ; Kloft C; Blankenstein O
    Eur J Endocrinol; 2017 Aug; 177(2):239-242. PubMed ID: 28512133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality control of extemporaneously prepared microdose captopril capsules: weight variation versus content uniformity.
    Colucci RD; Scavone JM; Auty R; Glassner-Cohen L
    Int J Clin Pharmacol Ther; 1994 Jan; 32(1):24-5. PubMed ID: 8199748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs.
    Feldman EC; Kass PH
    J Vet Intern Med; 2012; 26(4):1078-80. PubMed ID: 22708554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compounded Formulations of Dimethyl Fumarate Show Significant Variability in Product Characteristics.
    Boulas P
    Drug Res (Stuttg); 2016 May; 66(5):275-8. PubMed ID: 26697892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
    Cook AK; Bond KG
    J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective evaluation of the effect of trilostane on insulin requirement and fructosamine concentration in eight diabetic dogs with hyperadrenocorticism.
    McLauchlan G; Knottenbelt C; Augusto M; Helm J; McGrotty Y; Ramsey I
    J Small Anim Pract; 2010 Dec; 51(12):642-8. PubMed ID: 21121919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Most Frequently Prescribed Extemporaneously Compounded Veterinary Medications at a Large Independent Community Pharmacy.
    Karara AH; Hines R; Demir Z; Nnorom B; Horsey R; Twigg G
    Int J Pharm Compd; 2016; 20(6):461-467. PubMed ID: 28339384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products.
    Green DM; Jones AC; Brain KR
    J Clin Pharm Ther; 2012 Feb; 37(1):53-7. PubMed ID: 21501202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.